Free tool
Cell therapy stocks
We cover 5 companies grouped under the Cell therapy theme. The median market value in the group is $2.25B. Across the group, the median move over the past trading day is −2.04%. Price change over the past year runs from −23.9% to +147.6% across the middle 80 percent of the group, with a median of +4.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $4.02B | Mid cap | −40.44% | Nov 11, 2026 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | +233.88% | Nov 5, 2026 |
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | +1.03% | Aug 27, 2026 |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% | Aug 27, 2026 |
| VCEL | Vericel Corporation | $2.17B | Mid cap | +18.25% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.